Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 12;11(12):3288.
doi: 10.3390/biomedicines11123288.

Methylation Analysis of Urinary Sample in Non-Muscle-Invasive Bladder Carcinoma: Frequency and Management of Invalid Result

Francesco Pierconti  1 , E D Rossi  1 , V Fiorentino  2 , A Bakacs  1 , A Carlino  3 , E Navarra  1 , E Sacco  4 , A Totaro  4 , G Palermo  4 , L M Larocca  3 , M Martini  2
Affiliations

Methylation Analysis of Urinary Sample in Non-Muscle-Invasive Bladder Carcinoma: Frequency and Management of Invalid Result

Francesco Pierconti et al. Biomedicines. .

Abstract

Background: Numerous studies showed that methylation analysis represents a newly developed urinary marker based on DNA methylation changes in a panel of genomic biomarkers and it could represent a valid tool in terms of the diagnosis and prediction of high-grade urothelial carcinoma recurrences. One of the limits of the use of this new molecular method during a follow-up is represented by the number of invalid tests in routine practice.

Method: A total of 782 patients with a diagnosis of non-muscle-invasive high-grade carcinoma (NMIBC) was studied. The Bladder EpiCheck test (BE) was performed together with cytology in all cases within 1 year after the end of treatment. In 402 patients, the urinary samples were voided urine (UV), while, in 380 cases, the samples were collected after bladder washing (IU). For all the patients with invalid BE results, a second BE test was performed following the instructions for use that indicated the test should be repeated with a new urinary sample in the case of an invalid result.

Results: Analyzing the two different groups (UV and IU), we found the invalid BE results seemed to be not related to urinary samples (p = 0.13 Fisher's exact test), suggesting that the collection method was not relevant in order to reduce the number of invalid tests.

Conclusions: In the follow-up for NMIBC, for patients for whom a BE test is planned, a combined approach of cytology and a methylation test is recommended in order to repeat the BE test with an invalid result only in those cases with a cytological diagnosis of atypical urothelial cells (AUC) suspicious for high-grade urothelial carcinoma (SHGUC) and high-grade urothelial carcinoma (HGUC).

Keywords: bladder carcinoma; methylation analysis; non-muscle-invasive carcinoma; urinary cytology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Babjuk M., Burger M., Compérat E.M., Gontero P., Mostafid A.H., Palou J., van Rhijn B.W.G., Roupret M., Shariat S.F., Sylvester R., et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—2019 Update. Eur. Urol. 2019;76:639–657. doi: 10.1016/j.eururo.2019.08.016. - DOI - PubMed
    1. Witjes J.A., Morote J., Cornel E.B., Gakis G., van Valenberg G.J.P., Lozano F., Sternberg I.A., Willemsen E., Hegemann M.L., Paitan Y., et al. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial. Eur. Urol. Oncol. 2018;1:307–313. doi: 10.1016/j.euo.2018.06.011. - DOI - PubMed
    1. D’Andrea D., Soria F., Zehetmayer S., Gust K.M., Korn S., Witjes J.A., Shariat S.F. Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer. BJU Int. 2019;123:959–967. doi: 10.1111/bju.14673. - DOI - PMC - PubMed
    1. Pierconti F., Martini M., Fiorentino V., Cenci T., Racioppi M., Foschi N., Di Gianfrancesco L., Sacco E., Rossi E., Larocca L.M., et al. Upper urothelial tract high-grade carcinoma: Comparison of urine cytology and DNA methylation analysis in urinary samples. Hum. Pathol. 2021;118:42–48. doi: 10.1016/j.humpath.2021.09.007. - DOI - PubMed
    1. Pierconti F., Martini M., Cenci T., Fiorentino V., Sacco E., Bientinesi R., Pugliese D., Iacovelli R., Schinzari G., Larocca L.M., et al. Methylation study of the Paris system for reporting urinary (TPS) categories. J. Clin. Pathol. 2021;74:102–105. doi: 10.1136/jclinpath-2020-206633. - DOI - PubMed

LinkOut - more resources